Daniel H. Zimmerman Ph.D.
Net Worth
Last updated:
What is Daniel H. Zimmerman Ph.D. net worth?
The estimated net worth of Dr. Daniel H. Zimmerman Ph.D. is at least $6,548,289 as of 26 Feb 2020. He owns shares worth $987,160 as insider, has earned $82,909 from insider trading and has received compensation worth at least $5,478,220 in CEL-SCI Corporation.
What is the salary of Daniel H. Zimmerman Ph.D.?
Dr. Daniel H. Zimmerman Ph.D. salary is $249,010 per year as Senior Vice President of Research & Cellular Immunology in CEL-SCI Corporation.
How old is Daniel H. Zimmerman Ph.D.?
Dr. Daniel H. Zimmerman Ph.D. is 84 years old, born in 1941.
What stocks does Daniel H. Zimmerman Ph.D. currently own?
As insider, Dr. Daniel H. Zimmerman Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| CEL-SCI Corporation (CVM) | Senior Vice President of Research & Cellular Immunology | 114,387 | $8.63 | $987,160 |
What does CEL-SCI Corporation do?
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Daniel H. Zimmerman Ph.D. insider trading
CEL-SCI Corporation
Dr. Daniel H. Zimmerman Ph.D. has made 3 insider trades between 2003-2020, according to the Form 4 filled with the SEC. Most recently he purchased 923 units of CVM stock worth $9,996 on 26 Feb 2020.
The largest trade he's ever made was exercising 42,000 units of CVM stock on 2 Oct 2007. As of 26 Feb 2020 he still owns at least 114,387 units of CVM stock.
CEL-SCI key executives
CEL-SCI Corporation executives and other stock owners filed with the SEC:
- Dr. Daniel H. Zimmerman Ph.D. (84) Senior Vice President of Research & Cellular Immunology
- Dr. Eyal Talor Ph.D. (69) Chief Scientific Officer
- Mr. Geert R. Kersten (66) Chief Executive Officer, Principal Accounting & Financial Officer, Treasurer and Director
- Mr. John Cipriano (83) Senior Vice President of Regulatory Affairs
- Ms. Patricia B. Prichep (74) Senior Vice President of Operations & Corporation Sec.